中文摘要：

目的：总结雷珠单抗联合黄斑区格栅样光凝（GLP）治疗视网膜分支静脉阻塞（BRVO）继发黄囊斑样水肿（CME）患者的效果及不良反应发生情况。方法：选取2014年7月-2015年5月本院收治的BRVO继发CME患者60例作为研究对象，将其随机分为3组，每组20例，A组给予单纯GLP治疗，B组给予单纯玻璃体腔内雷珠单抗注射治疗，C组给予玻璃体腔内雷珠单抗注射联合GLP治疗，比较三组治疗前后最佳矫正视力（BCVA）、黄斑中心凹厚度（CMT）、治疗效果及不良反应发生率。结果：三组患者治疗前BCVA和CMT比较差异均无统计学意义（P〉0．05），治疗后BCVA均呈升高趋势，CMT均呈降低趋势，随访1、3、6个月C组BCVA均高于A、B组，CMT均低于A、B组，比较差异均有统计学意义（P〈0．05），而A、B组间BCVA和CMT比较差异均无统计学意义（P〉0．05）；完成6个月随访后，C组治疗总有效率明显高于A、B组，比较差异均有统计学意义（P〈0．05），而A、B组间比较差异无统计学意义（P〉0．05）；三组不良反应发生率比较差异无统计学意义（P〉0．05）。结论：雷珠单抗联合GLP治疗可有效的提高BRVO继发CME的治疗效果，并不增加不良反应的发生率。

英文摘要：

Objective： To summarize the application effect and adverse reaction conditions of ranibizumab treatment combined with macular grid photocoagulation in branch retinal vein occlusion （ BRVO ） secondary yellow cystic edema （ CME ） patients. Method： From July 2014 to May 2015, 60 cases of BRVO secondary CME in our hospital were selected as the research objects, they were randomly divided into three groups, each group had 20 cases.Group A was given pure GLP treatment, group B was given simple monoelonal ranibizumab antibody injection treatment, group C was given monoclonal ranibizumab antibody combined with maeular grid photocoagulation, the best corrected visual acuity （ BCVA ）, macular central thickness （ CMT ）, treatment effect and adverse reaction rate were compared among three groups before and after treatment.Result： There were no significant differences in CMT and BCVA among three groups before treatment （ P〉0.05 ）, BCVA showed an increasing trend and CMT showed a decreasing trend in three groups after treatment, followed up 1, 3 and 6 months, the BCVA of group C was higher than group A and B, the CMT was lower than group A and B, the differences were statistically significant （ P〈0.05 ）, the differences of CMT and BCVA in group A and B were not statistically significant （ P〉O.05 ） .After 6 months followed-up, the total effective rate of group C were significantly higher than that of the group A and group B, the differences were statistically significant （ P〈0.05 ）, but there was no statistically significant （ P〉0.05 ） .There were no significant differences in the incidence of adverse reactions among three groups （ P〉0.05 ） . Conclusion： Ranibizumab treatment combine with macular grid photocoagulation can effectively improve the therapeutic effect of BRVO secondary CME, does not increase the incidence of adverse reactions.